Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Venetoclax
Related studies linked through entity extraction aliases.
Venetoclax and Romidepsin in Treating Patients With Recurrent or Refractory Mature T-Cell Lymphoma
- Status
- COMPLETED
- Phase
- PHASE2
A Clinical Trial to Learn About the Study Medicine Called Maplirpacept (PF-07901801), Alone and When Used in Combination With Other Medicines to Treat Participants With Advanced Hematological Malignancies, Including Lymphoma, Leukemia and Multiple Myeloma
- Status
- TERMINATED
- Phase
- PHASE1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Venetoclax and Ibrutinib in Treating in Participants With Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Venetoclax, Lenalidomide and Rituximab in Patients With Relapsed/Refractory Mantle Cell Lymphoma
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
A Study Of The Selective PKC-β Inhibitor MS- 553
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Venetoclax and Dinaciclib (MK7965) in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- TERMINATED
- Phase
- PHASE1
Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
A Study of Venetoclax and Rituximab/Hyaluronidase Human in Relapsed/Refractory CLL
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Activity and Safety of Front-line Venetoclax and Rituximab in Young and Fit Patients With Chronic Lymphocytic Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia
- Status
- COMPLETED
- Phase
- PHASE2
A Study of Venetoclax and Alvocidib in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Venetoclax With High-dose Ibrutinib for CLL Progressing on Single Agent Ibrutinib
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1
A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy
- Status
- COMPLETED
- Phase
- PHASE3
Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome
- Status
- TERMINATED
- Phase
- PHASE2
Venetoclax, Ixazomib Citrate, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma
- Status
- COMPLETED
- Phase
- PHASE1